Skip to main content

Table 1 Baseline characteristics of participants

From: GCKR common functional polymorphisms are associated with metabolic syndrome and its components: a 10-year retrospective cohort study in Iranian adults

  Total rs780094 rs780093 rs1260326
CC (n = 2543) CT (n = 4169) TT (n = 1879) CC (n = 2509) CT (n = 4180) TT (n = 1902) CC (n = 2478) CT (n = 4174) TT (n = 1939)
With MetS 50.9% 28.1% 49% 23%* 28.2% 48% 23.8%* 27.4% 49.0% 23.6%*
Without MetS 49.1% 32.5% 47.1% 20.4%* 31.6% 48.2% 20.2%* 31.4% 47.7% 20.9%*
Male 42.6% 30.9% 47.8% 21.2% 30.8% 47.5% 21.6% 30.3% 48.0% 21.8%
Female 57.4% 29.7% 48.0% 22.2% 29.3% 48.4% 22.3% 28.8% 48.5% 22.7%
Smoking never 83% 30.6% 47.9% 21.5% 30.3% 48.0% 21.7% 29.7% 48.4% 21.9%
Ex-smoker and smoker 17% 28.0% 48.9% 23.1% 28.0% 49.0% 23.0% 27.8% 48.2% 23.9%
Age (years) 39 ± 16 39 ± 17 39 ± 16 40 ± 17 39 ± 17 39 ± 16 40 ± 17 39 ± 17 39 ± 16 39.5 ± 16.6
WC (cm) 85 ± 21 (53.3%)a 85 ± 21 85 ± 21 85 ± 22 85 ± 22 85 ± 21 85 ± 22 85 ± 22 85 ± 21 85.4 ± 21.5
HDL-C (mg/dl) 42 ± 14 (69.8%)b 43 ± 14 42 ± 14 42 ± 15 43 ± 14 42 ± 14 42 ± 14 43 ± 14 42 ± 14 42 ± 14
TG (mg/dl) 137 ± 86 (41.8%)c 125 ± 75 139 ± 88 150 ± 91 126 ± 81 137 ± 84 152 ± 92 125 ± 74 138 ± 88 151 ± 92
FBS (mg/dl) 89 ± 25 (22.3%)d 90 ± 26 89 ± 23 88 ± 27 90 ± 27 89 ± 23 89 ± 27 90 ± 27 89.4 ± 23.1 88.8 ± 26.5
SBP (mmHg) 110 ± 26(28.8%)e 110 ± 26 110 ± 25 111 ± 27 110 ± 26 110 ± 25 111 ± 26 110 ± 26 110 ± 26 111.1 ± 26
DBP (mmHg) 73 ± 17 (28.8%)e 72 ± 17 73 ± 17 73 ± 18 72 ± 18 73 ± 17 73 ± 18 72 ± 18 72 ± 17 73 ± 17
  1. From the 6th row onwards, data are presented as mean ± SD
  2. aFrequency of subjects with high waist circumference: waist circumference ≥ 90 cm for both genders
  3. bFrequency of subjects low HDL-C: HDL-C < 40 mg/dl in men and < 50 mg/dl in women and drug treatment
  4. cFrequency of subjects high TG: TG ≥ 150 mg/dl and drug treatment
  5. dFrequency of subjects high FBS: FBS ≥ 100 mg/dl and drug treatment
  6. eFrequency of subjects high blood pressure: SBP ≥ 130 mmHg and DBP ≥ 85 mmHg and drug treatment
  7. *Frequency differences of genotypes between MetS and without MetS, P < 0.05
  8. TT vs. CC, P < 0.05 and TT vs CT, P < 0.05
\